Biohit Oyj (BIOBV) Stock Overview
A biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BIOBV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biohit Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.73 |
| 52 Week High | €4.35 |
| 52 Week Low | €1.96 |
| Beta | 0.62 |
| 1 Month Change | 3.02% |
| 3 Month Change | -6.19% |
| 1 Year Change | 35.82% |
| 3 Year Change | 93.62% |
| 5 Year Change | 7.48% |
| Change since IPO | -45.51% |
Recent News & Updates
Biohit Oyj's (HEL:BIOBV) Promising Earnings May Rest On Soft Foundations
Feb 20
After Leaping 32% Biohit Oyj (HEL:BIOBV) Shares Are Not Flying Under The Radar
Jan 10Recent updates
Biohit Oyj's (HEL:BIOBV) Promising Earnings May Rest On Soft Foundations
Feb 20After Leaping 32% Biohit Oyj (HEL:BIOBV) Shares Are Not Flying Under The Radar
Jan 10Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals
Feb 22Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 17Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth
Aug 04Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth
Feb 09Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business
Aug 11Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business
Apr 13We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth
Dec 28Shareholder Returns
| BIOBV | FI Medical Equipment | FI Market | |
|---|---|---|---|
| 7D | 0.4% | 3.5% | 0.9% |
| 1Y | 35.8% | -1.2% | 2.5% |
Return vs Industry: BIOBV exceeded the Finnish Medical Equipment industry which returned -1.2% over the past year.
Return vs Market: BIOBV exceeded the Finnish Market which returned 2.5% over the past year.
Price Volatility
| BIOBV volatility | |
|---|---|
| BIOBV Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FI Market | 8.4% |
| 10% least volatile stocks in FI Market | 3.6% |
Stable Share Price: BIOBV has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: BIOBV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 46 | Jussi Hahtela | www.biohithealthcare.com |
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vitamin D, a test for determination of 25-hydroxyvitamin D2 and D3; and BIOHIT Calprotectin test, a quantitative test that provides a reliable differentiation between inflammatory bowel diseases and irritable bowel syndrome. It also offers GastroPanel quick test NT, a quantitative immunochromatographic test for the detection of Helicobacter pylori (H.
Biohit Oyj Fundamentals Summary
| BIOBV fundamental statistics | |
|---|---|
| Market cap | €41.46m |
| Earnings (TTM) | €2.57m |
| Revenue (TTM) | €14.28m |
Is BIOBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOBV income statement (TTM) | |
|---|---|
| Revenue | €14.28m |
| Cost of Revenue | €4.94m |
| Gross Profit | €9.34m |
| Other Expenses | €6.77m |
| Earnings | €2.57m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 65.39% |
| Net Profit Margin | 17.98% |
| Debt/Equity Ratio | 0% |
How did BIOBV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/09 01:01 |
| End of Day Share Price | 2025/06/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biohit Oyj is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antti Siltanen | Inderes Oy |